Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INNOVAR vs COLPREP KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Innovar is a combination of fentanyl (mu-opioid receptor agonist) and droperidol (butyrophenone antipsychotic that blocks dopamine D2 receptors in the CNS, producing sedation and antiemetic effects).
Col Prep Kit contains polyethylene glycol (PEG) 3350 and electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate). PEG is an osmotic agent that causes water retention in the colon, increasing stool volume and stimulating bowel movements. Electrolytes maintain fluid and electrolyte balance, preventing shifts during bowel cleansing.
Neuroleptanalgesia for surgical and diagnostic procedures,Adjunct to general anesthesia
Bowel cleansing prior to colonoscopy
2-5 m L (droperidol 2.5-5 mg and fentanyl 0.05-0.1 mg) IM/IV every 1-2 hours as needed for neuroleptanalgesia; surgical anesthesia: initial 1 m L/10 kg IM or slow IV, then 0.5 m L increments.
Colprep Kit (sodium picosulfate/magnesium oxide/citric acid) for bowel cleansing: Two doses administered orally. First dose: 1 sachet reconstituted in water in the evening prior to colonoscopy. Second dose: 1 sachet on the morning of the procedure, at least 5 hours before the procedure. Each sachet is dissolved in 150 m L water, diluted to a total volume of 500 m L, and consumed over 30-60 minutes followed by additional water.
Droperidol: terminal t1/2 2.2–2.5 h (infants 4.5 h). Fentanyl: terminal t1/2 3–7 h (mean ~4 h) in adults; prolonged in elderly (up to 16 h) and hepatic impairment.
Not applicable; colonic lavage solution with negligible systemic absorption.
Fentanyl: CYP3A4 to norfentanyl; Droperidol: CYP3A4 and CYP1A2 to multiple metabolites.
Polyethylene glycol (PEG) 3350 is minimally absorbed and not metabolized; it is excreted unchanged in feces. Electrolytes are absorbed and excreted renally.
Droperidol: ~75% renal as metabolites, ~22% biliary/fecal. Fentanyl: primarily renal as metabolites (85%), ~9% fecal.
Primarily fecal as unabsorbed drug; minimal renal excretion (<1%).
Fentanyl: ~80–85% bound to albumin and α1-acid glycoprotein. Droperidol: ~85–90% bound to albumin and α1-acid glycoprotein.
Not applicable; not absorbed systemically.
Fentanyl: Vd 3–5 L/kg (large distribution to tissues, slow elimination). Droperidol: Vd 1.5–2 L/kg (moderate distribution).
Not applicable; confined to gastrointestinal lumen.
Fentanyl: IV 100%; transdermal 92% (after depot formation); transmucosal ~50% (buccal) to 70% (nasal); oral <30% due to first-pass. Droperidol: IV 100%; IM ~85% (well absorbed).
Oral: <0.1% (negligible systemic absorption).
e GFR >60 m L/min: no adjustment; e GFR 30-60: reduce dose by 25-50% due to fentanyl accumulation; e GFR <30: avoid or use with extreme caution, reduce dose by ≥50%, monitor for respiratory depression.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-to-moderate impairment; use with caution and ensure adequate hydration.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated due to impaired fentanyl metabolism and increased sedation risk.
No dose adjustment required for mild-to-moderate hepatic impairment. Safety not established in severe hepatic impairment (Child-Pugh C); use with caution.
Not FDA-approved for pediatric use; limited data: 0.1 m L/kg (droperidol 0.125 mg/kg + fentanyl 0.0025 mg/kg) IM/IV as single dose; max 1.5 m L. Contraindicated in neonates.
Safety and efficacy not established in pediatric patients (<18 years). No approved pediatric dosing.
Reduce initial dose by 50-75% (e.g., 0.5-1 m L IM/IV); titrate cautiously; increased risk of hypotension, respiratory depression, and prolonged sedation; monitor renal function.
No specific dose adjustment. Use with caution due to increased risk of electrolyte disturbances and dehydration; ensure adequate hydration and monitor renal function.
Risk of respiratory depression, especially in elderly, debilitated, or opioid-naive patients; risk of QT prolongation and torsade de pointes with droperidol, including at recommended doses.
No FDA black box warning.
Monitor respiratory function; avoid in patients with bradycardia, electrolyte abnormalities, or QT prolongation; risk of hypotension, neuroleptic malignant syndrome, and extrapyramidal symptoms.
Risk of fluid and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypomagnesemia, seizures).,Cardiac arrhythmias in patients with electrolyte imbalances or prolonged QT interval.,Renal impairment: risk of acute phosphate nephropathy if using sodium phosphate-based products; however, this product contains sulfate and magnesium.,Gastric retention or gastrointestinal obstruction: do not use in patients with ileus, gastric retention, bowel obstruction, or perforation.,Aspiration risk: use with caution in patients with impaired gag reflex or those prone to regurgitation.
Hypersensitivity to fentanyl, droperidol, or components; known QT prolongation; concurrent MAOIs; severe respiratory depression; myasthenia gravis.
Gastrointestinal obstruction or ileus,Bowel perforation,Toxic colitis or toxic megacolon,Gastric retention,Known hypersensitivity to any component of the kit
Avoid grapefruit juice as it may increase fentanyl levels via CYP3A4 inhibition. No specific food restrictions for droperidol. Maintain adequate hydration to prevent hypotension, but monitor for fluid overload if cardiac compromise.
Avoid all solid foods, milk, yogurt, and any beverages containing pulp or red/purple coloring. Only clear liquids are permitted: water, clear broth (fat-free), apple juice, white grape juice, clear sodas (e.g., ginger ale), black coffee or tea (no milk or creamer). No alcohol. Ensure no dairy or citrus juices.
First trimester: Risk of congenital malformations, including cardiac and neural tube defects, associated with droperidol exposure. Second and third trimesters: Risk of extrapyramidal symptoms, neuroleptic malignant syndrome, and neonatal withdrawal. Fentanyl component may cause fetal respiratory depression and intrauterine growth restriction. Use only if maternal benefit outweighs fetal risk.
Colprep Kit contains polyethylene glycol and electrolytes. Polyethylene glycol is not teratogenic in animal studies; no human studies available. Risk to fetus during all trimesters is considered low due to minimal systemic absorption.
Fentanyl and droperidol are excreted in breast milk. Fentanyl M/P ratio approximately 0.2–0.4. Potential for sedation and respiratory depression in the infant. Avoid breast-feeding for 24 hours after administration. Discard milk during this period.
Polyethylene glycol is not absorbed systemically and is unlikely to pass into breast milk. M/P ratio not established. Considered compatible with breastfeeding.
No established dose adjustments for pregnancy. Increased clearance of fentanyl in third trimester may require higher doses for analgesic effect. Lower doses of droperidol recommended due to increased volume of distribution and prolonged effects. Use lowest effective dose and monitor for excessive sedation and hypotension.
No dose adjustment required in pregnancy due to minimal systemic absorption. Use caution if maternal comorbidities such as renal impairment or congestive heart failure present.
Innovar (droperidol + fentanyl) is a neuroleptanalgesic combination; monitor for respiratory depression, hypotension, and extrapyramidal symptoms. Droperidol prolongs QTc interval; avoid in patients with electrolyte disturbances or on QT-prolonging drugs. Fentanyl is a potent mu-opioid agonist; naloxone reversal may be needed. Onset of analgesia is rapid (<2 min IV), duration 30-60 min; droperidol's sedative effect lasts 2-4 hours. Use with caution in elderly, hypovolemic, or compromised patients.
Col Prep Kit contains sodium phosphate monobasic and sodium phosphate dibasic. Use with caution in patients with renal impairment, heart failure, or electrolyte abnormalities due to risk of phosphate nephropathy. Ensure adequate hydration before, during, and after administration. Monitor serum electrolytes, BUN, and creatinine in at-risk patients.
You may feel drowsy and lightheaded; avoid driving or operating machinery for 24 hours.,Report any difficulty breathing, slow or shallow breathing, or severe dizziness immediately.,Avoid alcohol and other sedatives while taking this medication.,Inform your doctor if you have a history of heart rhythm problems, low potassium, or low magnesium.,This drug can cause involuntary muscle movements or restlessness; notify your healthcare provider if these occur.
Take the medication exactly as prescribed, usually as a split dose the day before and the day of the procedure.,Drink plenty of clear liquids (e.g., water, clear broth, apple juice) to prevent dehydration.,Do not eat any solid food while taking this medication; only consume clear liquids.,Expect frequent, watery bowel movements starting within 1-2 hours of the first dose.,Contact your doctor if you experience severe abdominal pain, vomiting, or signs of dehydration (e.g., dizziness, decreased urination).,Stop taking other laxatives or stool softeners unless directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INNOVAR vs COLPREP KIT, answered by our medical review team.
INNOVAR is a Antipsychotic (Butyrophenone) that works by Innovar is a combination of fentanyl (mu-opioid receptor agonist) and droperidol (butyrophenone antipsychotic that blocks dopamine D2 receptors in the CNS, producing sedation and antiemetic effects).. COLPREP KIT is a Osmotic Laxative that works by Col Prep Kit contains polyethylene glycol (PEG) 3350 and electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate). PEG is an osmotic agent that causes water retention in the colon, increasing stool volume and stimulating bowel movements. Electrolytes maintain fluid and electrolyte balance, preventing shifts during bowel cleansing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INNOVAR and COLPREP KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INNOVAR is: 2-5 m L (droperidol 2.5-5 mg and fentanyl 0.05-0.1 mg) IM/IV every 1-2 hours as needed for neuroleptanalgesia; surgical anesthesia: initial 1 m L/10 kg IM or slow IV, then 0.5 m L increments.. The standard adult dose of COLPREP KIT is: Colprep Kit (sodium picosulfate/magnesium oxide/citric acid) for bowel cleansing: Two doses administered orally. First dose: 1 sachet reconstituted in water in the evening prior to colonoscopy. Second dose: 1 sachet on the morning of the procedure, at least 5 hours before the procedure. Each sachet is dissolved in 150 m L water, diluted to a total volume of 500 m L, and consumed over 30-60 minutes followed by additional water.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INNOVAR and COLPREP KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INNOVAR is classified as Category C. First trimester: Risk of congenital malformations, including cardiac and neural tube defects, associated with droperidol exposure. Second and third trimesters: Risk of extrapyramid. COLPREP KIT is classified as Category C. Colprep Kit contains polyethylene glycol and electrolytes. Polyethylene glycol is not teratogenic in animal studies; no human studies available. Risk to fetus during all trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.